Relmada Therapeutics, Inc. (RLMD)Healthcare | Biotechnology | Coral Gables, United States | NasdaqCM
4.33 USD
-0.19
(-4.204%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.33 |
Hot Take ↕ | Aug. 22, 2026, 5:33 a.m. EDT
The investment case for Relmada Therapeutics is currently defined by a severe disconnect between optimistic analyst targets and a deteriorating reality. Fundamentally, the company is trapped in a multi-year decline, having lost over 90% of its value since 2016, with the last three consecutive years seeing negative returns. This structural breakdown is compounded by a lack of profitability, negative free cash flow, and a trailing P/E that indicates no earnings base to support the current price. The balance sheet, while technically liquid due to low debt, is burning cash to fund R&D, a classic value trap for a biotech firm without a proven commercial product. The short-term outlook remains precarious. Despite a 'strong buy' recommendation and a lofty $19 price target from analysts, the market is pricing in continued distress. The recent price action shows the stock trading well below its moving averages, confirming a downtrend. Options activity confirms this pessimism, with traders aggressively buying puts to protect against further drops rather than betting on a recovery. The statistical forecasting model offers virtually no guidance, reflecting the high noise and low predictability typical of distressed small-cap biotechs. Until there is concrete evidence of a blockbuster drug approval or a shift to profitability, the risk of permanent capital loss outweighs the speculative upside. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.131634 |
| MSTL | 0.136653 |
| AutoETS | 0.138395 |
| AutoTheta | 0.174331 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 36.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.112 |
| Excess Kurtosis | -1.51 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.095 |
| Market Cap | 461,880,448 |
| Forward P/E | -7.73 |
| Website | https://www.relmada.com |
As of Aug. 22, 2026, 5:33 a.m. EDT: Speculators are overwhelmingly bearish, positioning heavy put volume relative to call volume across all expirations. While there is significant open interest in out-of-the-money calls at the $7.50 strike, the flow is dominated by protective puts, particularly the surge in volume for the $5.00 strike in February 2027, suggesting a hedge against further downside rather than a bet on a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.1830986 |
| Address1 | 2,222 Ponce de Leon Blvd. |
| Address2 | Floor 3 |
| All Time High | 80.0 |
| All Time Low | 0.24 |
| Ask | 5.55 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 818,220 |
| Average Daily Volume3 Month | 1,736,931 |
| Average Volume | 1,749,683 |
| Average Volume10Days | 818,220 |
| Bid | 3.24 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 10.152 |
| City | Coral Gables |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.33 |
| Current Ratio | 80.214 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.52 |
| Day Low | 4.32 |
| Debt To Equity | 0.095 |
| Display Name | Relmada Therapeutics |
| Dividend Date | 1,569,801,600 |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -13,855,048 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 4.835 |
| Enterprise Value | -66,994,720 |
| Eps Current Year | -0.48 |
| Eps Forward | -0.56 |
| Eps Trailing Twelve Months | -0.91 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.5704 |
| Fifty Day Average Change | -1.2404003 |
| Fifty Day Average Change Percent | -0.22267705 |
| Fifty Two Week Change Percent | 303.5714 |
| Fifty Two Week High | 8.0 |
| Fifty Two Week High Change | -3.67 |
| Fifty Two Week High Change Percent | -0.45875 |
| Fifty Two Week Low | 0.822 |
| Fifty Two Week Low Change | 3.508 |
| Fifty Two Week Low Change Percent | 4.2676396 |
| Fifty Two Week Range | 0.822 - 8.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,271,000,000 |
| Float Shares | 7,718,550 |
| Forward Eps | -0.56 |
| Forward P E | -7.732143 |
| Free Cashflow | -7,737,662 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Fullday Change | -0.19 |
| Fullday Change Percent | -4.20354 |
| Fullday Price | 4.33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02855 |
| Held Percent Institutions | 0.94567 |
| Implied Shares Outstanding | 106,669,846 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,569,801,600 |
| Last Split Factor | 1:4 |
| Long Business Summary | Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida. |
| Long Name | Relmada Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 461,880,448 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9070579 |
| Most Recent Quarter | 1,577,750,400 |
| Net Income To Common | -15,005,199 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 482,147,703 |
| Number Of Analyst Opinions | 6 |
| Open | 4.51 |
| Operating Cashflow | -12,092,784 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 786 629 1376 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.33 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 4.52 |
| Price Eps Current Year | -9.020833 |
| Price Hint | 4 |
| Price To Book | 0.42651692 |
| Profit Margins | 0.0 |
| Quick Ratio | 79.924 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.19 |
| Regular Market Change Percent | -4.20354 |
| Regular Market Day High | 4.52 |
| Regular Market Day Low | 4.32 |
| Regular Market Day Range | 4.32 - 4.52 |
| Regular Market Open | 4.51 |
| Regular Market Previous Close | 4.52 |
| Regular Market Price | 4.33 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 678,358 |
| Return On Assets | -0.14385 |
| Return On Equity | -0.25625 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 106,669,846 |
| Shares Percent Shares Out | 0.120900005 |
| Shares Short | 12,893,514 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 12,990,487 |
| Short Name | Relmada Therapeutics, Inc. |
| Short Percent Of Float | 0.1283 |
| Short Ratio | 8.33 |
| Source Interval | 15 |
| State | FL |
| Symbol | RLMD |
| Target High Price | 19.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 12.66667 |
| Target Median Price | 12.0 |
| Total Cash | 116,443,344 |
| Total Cash Per Share | 10.219 |
| Total Debt | 110,247 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.91 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.4557 |
| Two Hundred Day Average Change | -1.1257 |
| Two Hundred Day Average Change Percent | -0.20633467 |
| Type Disp | Equity |
| Volume | 678,358 |
| Website | https://www.relmada.com |
| Zip | 33,134 |